Seto Inland Sea cruise tours are targeting wealthy visitors, and Japan Airlines has revamped its domestic lounge at Haneda Airport. Hotel groups, ryokan owners, cruise operators...
Semiconductor and AI shares have driven the market's recent strength, while data centre operators, telecoms firms and cloud providers look for capital and anchor customers to...
The Nikkei closed above 70,000 on October 6 for the first time in three months on AI and semiconductor buying, and venture funds, corporate investors and university spinout...
Mitsui Fudosan intends to build a data center in an abandoned tunnel. Developers, REITs and institutional investors are seeking land, joint venture partners and long-term funding...
Broadcasters, streaming platforms, anime and game studios and creative agencies are looking for investors and distribution partners to scale across Asia, Europe and North America.
Fast Retailing results are viewed as the key corporate readout for Japan this week, while Suzuki's low-priced mini EV is reshaping competition in the auto market. Retailers,...
Japan Exchange Group has announced the biggest-ever Topix reshuffle, with 683 companies earmarked for removal and 35 additions, taking effect from October 30. The operator of Don...
Japan's four largest beer makers were searched on October 7 over suspected coordination of wholesale prices, a rare cartel investigation that could lead to criminal charges. Late...
TEPCO plans to use AI to speed nuclear restarts. Utilities, offshore wind developers, hydrogen producers and grid operators are lining up financing for generation, storage and...
Panasonic plans to make humanoid robots, leveraging its battery business, while Suzuki has launched a cheapest-in-class mini EV priced to undercut BYD in Japan. Component makers,...
Private-sector pay has reached a record 4.87 million yen, and real cash earnings rose 1.5% in August from a year earlier. Technology, robotics, semiconductor and manufacturing...
Shionogi has agreed to buy US-based IntraBio for $2 billion to expand its rare disease drug business. Pharmaceutical companies, hospital groups, medtech makers and health-tech...